Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4

2 months ago 31

Soumya Eswaran

Thu, April 2, 2026 astatine 8:41 AM CDT 3 min read

TimesSquare Capital Management, an equity concern absorption company, released its “U.S. Small Cap Growth Strategy” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The strategy returned 3.70% (gross) and 3.45% (net) successful the 4th fourth compared to a 1.22% instrumentality for the Russell 2000 Growth Index. In 2025, the strategy returned 6.91% (gross) and 5.85% (net) compared to 13.01% for the index. Global equity markets ended the 4th connected a affirmative note, with Europe leading, followed by Emerging Markets. In astir markets, ample caps outperformed tiny caps. The commercialized truce betwixt the United States and China was prolonged for an further year, but planetary geopolitical concerns, whether related to tariffs oregon not, persisted. Third-quarter GDP exceeded expectations, but user caution persists amid ongoing labor-market softening, influencing the Fed’s determination connected interest-rate cuts. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, TimesSquare Capital U.S. Small Cap Growth Strategy highlighted NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS). NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is simply a late-stage biopharmaceutical institution that develops therapies for cardiovascular diseases. The one-month instrumentality for NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) was 8.86%, and its shares gained 82.28% implicit the past 52 weeks. On April 1, 2026, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) banal closed astatine $32.81 per share, with a marketplace capitalization of $3.77 billion.

TimesSquare Capital U.S. Small Cap Growth Strategy stated the pursuing regarding NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) successful its 4th fourth 2025 capitalist letter:

"Our preferences among Health Care stocks are those companies providing caller therapies for unmet needs that bid premium pricing, oregon specialized work providers. Shares successful the biopharma developer of cholesterin inhibitors for cardiovascular diseases, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), roseate by 23%. Indications were powerfully affirmative for the upcoming proceedings results for its CETP inhibitor to trim LDL levels."

Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 37 hedge money portfolios held NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) astatine the extremity of the 4th quarter, up from 28 successful the erstwhile quarter. While we admit the imaginable of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article